Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Travere Therapeutics (NASDAQ: TVTX).The analyst commented, “We’d own TVTX for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE